Cargando…

Development of a Nomogram Model Predicting Current Bone Scan Positivity in Patients Treated with Androgen-Deprivation Therapy for Prostate Cancer

Purpose: To develop a nomogram predictive of current bone scan positivity in patients receiving androgen-deprivation therapy (ADT) for advanced prostate cancer; to augment clinical judgment and highlight patients in need of additional imaging investigations. Materials and methods: A retrospective ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gotto, Geoffrey T., Yu, Changhong, Bernstein, Melanie, Eastham, James A., Kattan, Michael W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209823/ https://www.ncbi.nlm.nih.gov/pubmed/25386410 http://dx.doi.org/10.3389/fonc.2014.00296

Ejemplares similares

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen-Deprivation Therapy and Cardiovascular Disease Risk – The Role of Exercise in Prostate Cancer Treatment
por: Wall, Bradley
Publicado: (2016)

Testicular recurrence of oligometastatic prostatic adenocarcinoma after 22 years of androgen deprivation therapy
por: Fortier, Alexa, et al.
Publicado: (2022)

Androgen Deprivation Therapy Combined With Particle Therapy for Prostate Cancer: A Systematic Review
por: Petersen, Stine Elleberg, et al.
Publicado: (2021)

Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy
por: Sun, Qi, et al.
Publicado: (2023)

Exceptional pathologic complete response achieved with androgen deprivation and docetaxel therapy in Gleason 10 prostate cancer
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy
por: Graff, Julie N., et al.
Publicado: (2020)

Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer
por: Kattan, Michael W., et al.
Publicado: (2020)

Is there still a role for bilateral orchidectomy in androgen-deprivation therapy for metastatic prostate cancer?
por: Atta, Mohamed Adel, et al.
Publicado: (2019)

Elevated testosterone on immunoassay in a patient with metastatic prostate cancer following androgen deprivation therapy and bilateral orchiectomy
por: Sarkar, Arjun, et al.
Publicado: (2021)

First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective Study
por: Viscuse, Paul V., et al.
Publicado: (2019)

Biomarkers to Evaluate Androgen Deprivation Therapy for Prostate Cancer and Risk of Alzheimer’s Disease and Neurodegeneration: Old Drugs, New Concerns
por: Achard, Vérane, et al.
Publicado: (2021)

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
por: Merseburger, Axel S., et al.
Publicado: (2016)

The REDUCE metagram: a comprehensive prediction tool for determining the utility of dutasteride chemoprevention in men at risk for prostate cancer
por: Nguyen, Carvell T., et al.
Publicado: (2012)

Prostate Cancer With Metastatic Lytic Bone Lesions: Positive Bone Scan Post Docetaxel Chemotherapy in the Setting of Clinically Successful Treatment
por: Bird, Victoria Yvonne, et al.
Publicado: (2016)

Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer
por: Shevach, Jeffrey, et al.
Publicado: (2015)

Muscle Loss During Androgen Deprivation Therapy Is Associated With Higher Risk of Non-Cancer Mortality in High-Risk Prostate Cancer
por: Chiang, Pai-Kai, et al.
Publicado: (2021)

Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy
por: Reza, Mariana, et al.
Publicado: (2014)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

A rare case of de novo large cell neuroendocrine carcinoma of the prostate with long-term survival after cystoprostatectomy and androgen deprivation
por: Miyakawa, Jimpei, et al.
Publicado: (2018)

Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues
por: Bagrodia, Aditya, et al.
Publicado: (2009)

A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy
por: Kiwata, Jacqueline L, et al.
Publicado: (2017)

Dynamic changes in PSA levels predict prognostic outcomes in prostate cancer patients undergoing androgen -deprivation therapy: A multicenter retrospective analysis
por: Hu, Mingqiu, et al.
Publicado: (2023)

Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
por: Morrison, Belinda F, et al.
Publicado: (2011)

Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases
por: Varenhorst, Eberhard, et al.
Publicado: (2016)

Effect of androgen deprivation therapy on bone mineral density in patients with prostate cancer
por: Ilyas, Kashaf, et al.
Publicado: (2022)

ETS-related gene (ERG) expression as a predictor of oncological outcomes in patients with high-grade prostate cancer treated with primary androgen deprivation therapy: a cohort study
por: Rezk, Mark, et al.
Publicado: (2019)

Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial
por: Yang, Dingyuan, et al.
Publicado: (2023)

Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Prostate Cancer
por: Delgado, Jessica, et al.
Publicado: (2022)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition
por: Taaffe, Dennis R., et al.
Publicado: (2018)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy
por: Shiota, Masaki, et al.
Publicado: (2018)

Does androgen deprivation impact associations between cognition and strength, fitness and function in community-dwelling men with prostate cancer? A cross-sectional study
por: Mundell, Niamh L, et al.
Publicado: (2021)

Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer
por: Parker, C C, et al.
Publicado: (2002)

Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy)
por: Aoki, Manabu, et al.
Publicado: (2014)

Risk Factors of Biochemical Failure in Locally Advanced Carcinoma Prostate Treated With Definitive External Beam Radiotherapy and Androgen Deprivation Therapy: Experience From Tertiary Care Center in North India
por: Sidhu, Manjinder, et al.
Publicado: (2021)

Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer
por: Wallis, Christopher J D, et al.
Publicado: (2021)

Comparative Efficacy of Combined Radiotherapy, Systemic Therapy, and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-Analysis and Systematic Review
por: Wang, Yuhan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3vmjvv9i6s096ulb8o6fjth8qr